CNAT News and Press, Conatus Pharmaceuticals From 12/10/18

"Nothing can dim the light that shines from within" - Maya Angelou Introduction Conatus Pharmaceuticals ( CNAT ) is a small cap ($52M) clinical stage biopharma. Emricasan, a dual anti-apoptotic/anti-inflammatory oral irreversible pan-caspase inhibitor, is its lead investigative P...

Conatus (CNAT) is a clinical-stage biotech company that is developing a pan-caspase protease inhibitor, emricasan, with Novartis' ( NVS ) help. Emricasan is undergoing 4 different trials, 3 of which are focused on non-alcoholic steatohepatitis ((NASH)). On December 5, 2018, it announced top-li...

Recently, Conatus Pharmaceuticals ( CNAT ) announced results from its phase 2b ENCORE-PH study treating patients with NASH cirrhosis portal hypertension. The primary endpoint for the overall trial wasn't met. However, I believe that the company still has a path forward for a subpopulation ...

NEW YORK, NY / ACCESSWIRE / November 5, 2018 / Conatus Pharmaceuticals and Titan Pharmaceuticals were both seeing gains in Friday’s trading session. There was no news to explain Titan shares jumping but Conatus reported third quarter results and an update on its trials last week. RD...

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more ...

Conatus Pharmaceuticals ( CNAT ) Q3 results: Revenues: $7.7M (-19.8%). More news on: Conatus Pharmaceuticals, Healthcare stocks news, Earnings news and commentary, , Read more ...

Conatus Pharmaceuticals (CNAT) Q3 2018 Earnings Conference Call November 01, 2018, 04:30 PM ET Executives Alan Engbring - Executive Director of IR and Corporate Communications Steve Mento - President and CEO Keith Marshall - EVP, COO and CFO Analysts Yasmeen Rahimi - ROTH C...

Conatus Pharmaceuticals (NASDAQ: CNAT ): Q3 GAAP EPS of -$0.15 in-line. Revenue of $7.66M (-19.9% Y/Y) misses by $2.12M . Press Release More news on: Conatus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, ,

SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and nine months ended September 30, ...

SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the third quarter ended September 30, 2018, after the market close on Thursday, November 1, 2018. Conatus will host a conference call and audio w...